Roivant Sciences Ltd. 4

Director James C. Momtazee had 2,905 Roivant Sciences Ltd. common shares withheld for taxes upon vesting of prior equity awards, leaving him with 106,905 shares directly owned.

On September 10, 2026, director James C. Momtazee had 2,905 Roivant Sciences Ltd. common shares withheld in a Form 4-reported transaction characterized as a net share settlement to cover tax withholding obligations upon the vesting of previously granted equity under the company's Non-Employee Director Compensation Plan. The shares were effectively surrendered at an implied price of $40.94 per share, for an estimated value of about $119,000, reducing his directly held ownership to 106,905 common shares following the transaction. As this is a tax-related, compensation-driven withholding rather than an open-market sale or discretionary trade, it is best interpreted as routine equity compensation administration rather than a directional signal on the stock.

Filing Facts

CIK

1635088

Ticker

ROIV

Form

4

Source Type

fda

Accession

0001209181-26-000005

Alert Tier

5